Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | KYNU | Q16719 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119161 | 1.00 | CTSL (0.54) | CTSLCTSBCTSSALDH1A1ALOX15 | |
| SCHEMBL3604303 | 1.00 | CTSL (0.54) | CTSLCTSBCTSSALDH1A1ALOX15 | |
| SCHEMBL5409927 | 0.83 | ITGB3 (0.58) | — | |
| SCHEMBL17054213 | 0.82 | PTPN1 (0.44) | TAS1R3TAS1R1 | |
| SCHEMBL27664973 | 0.82 | TYR (0.55) | CTSLCTSBCTSSALDH1A1ALOX15 | |
| SCHEMBL13053322 | 0.82 | TYR (0.55) | CTSLCTSBCTSSALDH1A1ALOX15 | |
| SCHEMBL5400674 | 0.82 | ITGB3 (0.56) | MEN1KMT2A | |
| SCHEMBL5400669 | 0.82 | ITGB3 (0.56) | MEN1KMT2A | |
| SCHEMBL7151822 | 0.81 | ALDH1A1 (0.74) | CTSLCTSBCTSSALDH1A1ALOX15 | |
| SCHEMBL329686 | 0.81 | ALDH1A1 (0.74) | CTSLCTSBCTSSALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-RE47302-E1 | Peptide epoxyketone immunoproteasome inhibitors | ONYX THERAPEUTICS INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| EP-1539766-B1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-7842808-B2 | calcitonin gene-related peptide receptors antagonists such as 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid[2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide, used for treating headaches, pain, hot flashes or respiratory system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1689493-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005065779-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1539766-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2003104236-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | CTSL 86/4885CTSB 60/4885CTSS 137/4885 |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | CTSL 839/4885CTSB 374/4885CTSS 531/4885 |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | VDAC1, HTR3B, FAAH | CTSL 1017/4885CTSB 364/4885CTSS 474/4885 |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | CALCRL, CALCR, CALCA | CTSL 902/4885CTSB 407/4885CTSS 473/4885 |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | CTSL 86/4885CTSB 60/4885CTSS 137/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | CTSL 86/4885CTSB 60/4885CTSS 137/4885 |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | CALCRL, CALCR, CALCA | CTSL 893/4885CTSB 424/4885CTSS 485/4885 |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | CTSL 86/4885CTSB 60/4885CTSS 137/4885 |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | CTSL 86/4885CTSB 60/4885CTSS 137/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | CTSL 839/4885CTSB 374/4885CTSS 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.